Genetic and epigenetic alterations as hallmarks of the intricate road to cancer

[1]  P. Claudio,et al.  Molecular basis of angiogenesis and cancer , 2003, Oncogene.

[2]  A. Senderowicz.  Small-molecule cyclin-dependent kinase modulators , 2003, Oncogene.

[3]  A. Giordano,et al.  Emerging roles of DNA tumor viruses in cell proliferation: new insights into genomic instability , 2003, Oncogene.

[4]  Caterina Cinti,et al.  pRb2/p130-E2F4/5-HDAC1-SUV39H1-p300 and pRb2/p130-E2F4/5-HDAC1-SUV39H1-DNMT1 multimolecular complexes mediate the transcription of estrogen receptor-α in breast cancer , 2003, Oncogene.

[5]  Dario La Sala,et al.  Triggering of p73-dependent apoptosis in osteosarcoma is under the control of E2Fs–pRb2/p130 complexes , 2003, Oncogene.

[6]  S. Frank.  Somatic Mutation: Early Cancer Steps Depend on Tissue Architecture , 2003, Current Biology.

[7]  W. Hahn,et al.  Abolition of Cyclin-Dependent Kinase Inhibitor p16Ink4a and p21Cip1/Waf1 Functions Permits Ras-Induced Anchorage-Independent Growth in Telomerase-Immortalized Human Fibroblasts , 2003, Molecular and Cellular Biology.

[8]  T. Kalebic.  Epigenetic Changes: Potential Therapeutic Targets , 2003, Annals of the New York Academy of Sciences.

[9]  Y. Mitani,et al.  Histone Acetylation and Gastrointestinal Carcinogenesis , 2003, Annals of the New York Academy of Sciences.

[10]  Jose M. Silva,et al.  Concomitant expression of p16INK4a and p14ARF in primary breast cancer and analysis of inactivation mechanisms , 2003, The Journal of pathology.

[11]  K. Muegge,et al.  Epigenetic Control during Lymphoid Development and Immune Responses , 2003, Annals of the New York Academy of Sciences.

[12]  Max Costa,et al.  Epigenetics and the Environment , 2003, Annals of the New York Academy of Sciences.

[13]  K. Nephew,et al.  Epigenetic gene silencing in cancer initiation and progression. , 2003, Cancer letters.

[14]  G. Konopka,et al.  Signaling pathways regulating gliomagenesis. , 2003, Current molecular medicine.

[15]  W. Travis,et al.  The P16/cyclin D1/Rb pathway in neuroendocrine tumors of the lung. , 2003, Human pathology.

[16]  P. Maini,et al.  Mathematical oncology: Cancer summed up , 2003, Nature.

[17]  William C Hahn,et al.  Rules for making human tumor cells. , 2002, The New England journal of medicine.

[18]  J. Minna,et al.  Aberrant DNA methylation in lung cancer: biological and clinical implications. , 2002, The oncologist.

[19]  C. Cinti,et al.  Ras family genes: An interesting link between cell cycle and cancer , 2002, Journal of cellular physiology.

[20]  F. McCormick,et al.  The RB and p53 pathways in cancer. , 2002, Cancer cell.

[21]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[22]  T. Sandal.  Molecular aspects of the mammalian cell cycle and cancer. , 2002, The oncologist.

[23]  H. Ding,et al.  Induction of apoptosis in cancer: new therapeutic opportunities , 2002, Annals of medicine.

[24]  J. Herman,et al.  DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. , 2001, Human molecular genetics.

[25]  C. Cinti,et al.  pRb2/p130 and p107 control cell growth by multiple strategies and in association with different compartments within the nucleus * , 2001, Journal of cellular physiology.

[26]  I. Modlin,et al.  Cyclin D1 Antisense Oligonucleotide Inhibits Cell Growth Stimulated by Epidermal Growth Factor and Induces Apoptosis of Gastric Cancer Cells , 2001, Japanese journal of cancer research : Gann.

[27]  T. Owa,et al.  Cell cycle regulation in the G1 phase: a promising target for the development of new chemotherapeutic anticancer agents. , 2001, Current medicinal chemistry.

[28]  P. Beard,et al.  Virus-mediated killing of cells that lack p53 activity , 2001, Nature.

[29]  S. Corsale,et al.  DNA aneuploidy and high proliferative activity but not K‐ras‐2 mutations as independent predictors of clinical outcome in operable gastric carcinoma , 2001, Cancer.

[30]  Y. Geng,et al.  Specific protection against breast cancers by cyclin D1 ablation , 2001, Nature.

[31]  J. Hayes,et al.  Nucleosomes and the chromatin fiber. , 2001, Current opinion in genetics & development.

[32]  W. Lee,et al.  The retinoblastoma gene: a prototypic and multifunctional tumor suppressor. , 2001, Experimental cell research.

[33]  P. Hamel,et al.  Integration of the PRB and P53 Cell Cycle Control Pathways , 2001, Journal of Neuro-Oncology.

[34]  J. Wiencke,et al.  Correlations of partial and extensive methylation at the p14(ARF) locus with reduced mRNA expression in colorectal cancer cell lines and clinicopathological features in primary tumors. , 2000, Carcinogenesis.

[35]  Y. Yuasa,et al.  Alterations and hypermethylation of the p14ARF gene in gastric cancer , 2000, International journal of cancer.

[36]  Erwin G. Van Meir,et al.  p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma , 2000, Oncogene.

[37]  Jerry L. Workman,et al.  ATP-Dependent Chromatin-Remodeling Complexes , 2000, Molecular and Cellular Biology.

[38]  C. Allis,et al.  The language of covalent histone modifications , 2000, Nature.

[39]  A. Bird,et al.  Methylation-Induced Repression— Belts, Braces, and Chromatin , 1999, Cell.

[40]  W. Kaelin,et al.  Functions of the retinoblastoma protein. , 1999, BioEssays : news and reviews in molecular, cellular and developmental biology.

[41]  Robert A. Weinberg,et al.  Creation of human tumour cells with defined genetic elements , 1999, Nature.

[42]  L. Meijer,et al.  Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity. , 1999, Journal of medicinal chemistry.

[43]  D. Dean,et al.  Active Transcriptional Repression by the Rb–E2F Complex Mediates G1 Arrest Triggered by p16INK4a, TGFβ, and Contact Inhibition , 1999, Cell.

[44]  Frank McCormick,et al.  β-Catenin regulates expression of cyclin D1 in colon carcinoma cells , 1999, Nature.

[45]  M. Linsenmeyer,et al.  DNA methylation in the promoter region of the p16 (CDKN2/MTS-1/INK4A) gene in human breast tumours , 1999, British Journal of Cancer.

[46]  K. Kinzler,et al.  Genetic instabilities in human cancers , 1998, Nature.

[47]  A. Giaccia,et al.  The complexity of p53 modulation: emerging patterns from divergent signals. , 1998, Genes & development.

[48]  W. Yu,et al.  Requirement for Specific Proteases in Cancer Cell Intravasation as Revealed by a Novel Semiquantitative PCR-Based Assay , 1998, Cell.

[49]  N. Dyson.  The regulation of E2F by pRB-family proteins. , 1998, Genes & development.

[50]  J. Strouboulis,et al.  Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription , 1998, Nature Genetics.

[51]  Colin A. Johnson,et al.  Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex , 1998, Nature.

[52]  Yue Xiong,et al.  ARF Promotes MDM2 Degradation and Stabilizes p53: ARF-INK4a Locus Deletion Impairs Both the Rb and p53 Tumor Suppression Pathways , 1998, Cell.

[53]  J. Yokota,et al.  Expression of the Elm1 Gene, a Novel Gene of the CCN (Connective Tissue Growth Factor, Cyr61/Cef10, and Neuroblastoma Overexpressed Gene) Family, Suppresses In Vivo Tumor Growth and Metastasis of K-1735 Murine Melanoma Cells , 1998, The Journal of experimental medicine.

[54]  S. Mittnacht,et al.  Control of pRB phosphorylation. , 1998, Current opinion in genetics & development.

[55]  R H Hruban,et al.  Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas. , 1998, The American journal of surgical pathology.

[56]  M. Oren,et al.  Mdm2 promotes the rapid degradation of p53 , 1997, Nature.

[57]  Bert Vogelstein,et al.  Gatekeepers and caretakers , 1997, Nature.

[58]  E. Hovig,et al.  Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas. , 1996, British Journal of Cancer.

[59]  K. Kinzler,et al.  Life (and death) in a malignant tumour , 1996, Nature.

[60]  Kathleen R. Cho,et al.  Frequency of homozygous deletion at p16/CDKN2 in primary human tumours , 1995, Nature Genetics.

[61]  J. Barrett,et al.  KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. , 1995, Science.

[62]  L. Hartwell,et al.  Cell cycle control and cancer. , 1994, Science.

[63]  John G. Collard,et al.  Identification of an invasion-inducing gene, Tiam-1, that encodes a protein with homology to GDP-GTP exchangers for Rho-like proteins , 1994, Cell.

[64]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[65]  H. Varmus,et al.  Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. , 1984, Science.

[66]  John Cairns,et al.  Mutation selection and the natural history of cancer , 1975, Nature.

[67]  P. Steeg,et al.  Cyclins and breast cancer , 2004, Breast Cancer Research and Treatment.

[68]  L. Yamasaki.  Role of the RB tumor suppressor in cancer. , 2003, Cancer treatment and research.

[69]  Robert A. Weinberg,et al.  Metastasis genes: A progression puzzle , 2002, Nature.

[70]  D. Miller,et al.  Incidence of p14ARF gene deletion in high-grade adult and pediatric astrocytomas. , 2000, Human pathology.

[71]  J. Herman,et al.  Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer , 1999, Nature Genetics.

[72]  Peter W. Laird,et al.  THE ROLE OF DNA METHYLATION IN CANCER GENETICS AND EPIGENETICS , 1996 .

[73]  L. Meijer.  Chemical inhibitors of cyclin-dependent kinases. , 1995, Progress in cell cycle research.